News about "Phase 3 autoimmune myositis trial"

argenx Reports Positive Phase 3 ALKIVIA Results for Efgartigimod in Autoimmune Myositis

argenx Reports Positive Phase 3 ALKIVIA Results for Efgartigimod in Autoimmune Myositis

argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis, meeting the primary endpoint with sustained patient improvements.

Phase 3 Autoimmune Myositis Trial | 17/08/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members